Table 2

Clinical characteristics of the patients in the events investigated.

Parameter
Total evaluations (%)
Evaluations in VAP group (%)

Number of evaluations
219 (100%)
38 (100%)
Tracheostomy (n [%])
59 (26.9%)
10 (26.3%)
Atelectasisa (n [%])
13 (6.0%)
6 (15.7%)
Lung edemaa (n [%])
35 (16.0%)
9 (23.6%)
Lung contusiona (n [%])
6 (2.7%)
1 (2.6%)
Pleural effusiona (n [%])
21 (9,5%)
8 (21.0%)
Previous lung disease (n [%])
30 (13.6%)
6 (15.7%)
          COPD
16 (7.3%)
3 (7.8%)
          Cancer
11 (5.0%)
2 (5.2%)
          Asthma
2 (0.9%)
1 (2.6%)
          Pulmonary fibrosis
1 (0.4%)
None
Broncoaspiration (n [%])
12 (5.4%)
3 (7.8%)
Sepsis (n [%])
46 (21.0%)
14 (36.8%)
ARDS (n [%])
12 (5,4%)
3 (7.8%)
Renal failure (n [%]; creatinine >2.0 mg/dl)
91 (41.5%)
20 (52.6%)
Diabetes (n [%])
35 (16.0%)
5 (13.1%)
Chemotherapy (n [%])
13 (6.0%)
2 (5.2%)
Radiotherapy (n [%])
2 (0.9%)
None
Immunossupressants drugs (n [%])
5 (2.2%)
1 (2.6%)
AIDS (n [%])
3 (1.3%)
None
Renal transplantation (n [%])
5 (2.2%)
1 (2.6%)
Abdominal surgery (n [%])
32 (14.6%)
7 (18.4%)
Multiple trauma (n [%])
21 (9.5%)
3 (7.9%)
Neuromuscular blocking agents (n [%])
7 (3.1%)
7 (18.4%)
Central venous line (n [%])
215 (98.0%)
38 (100%)
Intracranial pressure monitoring (n [%])
20 (9.1%)
1 (2.6%)

aAccording to clinical judgement. ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; VAP, ventilator-associated pneumonia.

Camargo et al. Critical Care 2004 8:R422   doi:10.1186/cc2965